TherapeuticsMD (TXMD) Reports Q4 Loss of $0.10/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
TherapeuticsMD Announces Fourth Quarter and Full-Year 2014 Financial Results
March 10, 2015 4:09 PM EDTCurrent womens health product sales increased by 71 percent over prior year
Cash balance strengthened following recent equity financing of $59.1 million in net proceeds
Management to host conference call today at 4:30 p.m. EDT
BOCA RATON, Fla.--(BUSINESS WIRE)-- TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative womens healthcare company, today announced its fourth quarter and full-year financial results for the period ending Dec. 31, 2014.
2014 and recent corporate developments
Net revenue increased to approximately $15.0 million in 2014 compared with approximately $8.8 million in the prior... MorePhysicians’ Visual Assessments Correlate with Objective Measurements of Postmenopausal VVA Patients Treated with TX-004HR VagiCap
March 9, 2015 8:00 AM EDTNew data from 14-day phase 2 pilot study featured at ENDO 2015 show visual assessments may be appropriate to establish patient need and treatment response
BOCA RATON, Fla.--(BUSINESS WIRE)-- TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative womens healthcare company, presented at the Endocrine Societys 97th annual meeting new data showing healthcare providers visual assessments of vulvar and vaginal atrophy (VVA) before and after treatment with the investigational drug TX-004HR in the VagiCap dosage form correlated with significant changes in vaginal cellular response and pH in postmenopausal women with VVA.
... More